Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ON-01910 是一种非 ATP 竞争性 PLK1 抑制剂(IC50 为 9 nM,在无细胞试验中)。它对 Plk2 的选择性高出 30 倍,对 Plk3 没有活性。 Rigosertib 抑制 PI3K/Akt 通路并激活氧化应激信号。 Rigosertib 可诱导多种癌细胞凋亡。它是一种合成的苄基苯乙烯基砜类似物,具有潜在的抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 295 | 现货 | ||
2 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 997 | 现货 | ||
25 mg | ¥ 1,950 | 现货 | ||
50 mg | ¥ 2,990 | 现货 | ||
100 mg | ¥ 4,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 689 | 现货 |
产品描述 | ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay). It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells.It is a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. |
靶点活性 | PDGFR:18 nM(Cell-free assay) , FLK1:42 nM(Cell-free assay) , PLK1:9 nM(Cell-free assay) , BCR-ABL:32 nM(Cell-free assay) , Src:55 nM(Cell-free assay) |
体外活性 | ON01910, a small molecule inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis.?This compound was not ATP-competitive, but competed for the substrate binding site of the enzyme[1]. |
体内活性 | In vivo, this compound did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models.?ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors[1]. |
别名 | N-[2-甲氧基-5-[[[2-(2,4,6-三甲氧基苯基)乙烯基]磺酰]甲基]苯基]甘氨酸钠盐, (E/Z) ON-01910 sodium |
分子量 | 473.47 |
分子式 | C21H24NNaO8S |
CAS No. | 1225497-78-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 94 mg/mL (198.53 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1121 mL | 10.5603 mL | 21.1207 mL | 52.8017 mL |
5 mM | 0.4224 mL | 2.1121 mL | 4.2241 mL | 10.5603 mL | |
10 mM | 0.2112 mL | 1.056 mL | 2.1121 mL | 5.2802 mL | |
20 mM | 0.1056 mL | 0.528 mL | 1.056 mL | 2.6401 mL | |
50 mM | 0.0422 mL | 0.2112 mL | 0.4224 mL | 1.056 mL | |
100 mM | 0.0211 mL | 0.1056 mL | 0.2112 mL | 0.528 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(E/Z)-Rigosertib sodium 1225497-78-8 Cell Cycle/Checkpoint PLK ON01910 ON-01910 N-[2-甲氧基-5-[[[2-(2,4,6-三甲氧基苯基)乙烯基]磺酰]甲基]苯基]甘氨酸钠盐 ON 01910 (E/Z) ON-01910 sodium Inhibitor inhibitor inhibit